{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:10:38Z","timestamp":1773281438576,"version":"3.50.1"},"reference-count":17,"publisher":"The Society for Antibacterial and Antifungal Agents, Japan","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biocontrol Sci."],"published-print":{"date-parts":[[2012]]},"DOI":"10.4265\/bio.17.115","type":"journal-article","created":{"date-parts":[[2012,9,21]],"date-time":"2012-09-21T22:30:32Z","timestamp":1348266632000},"page":"115-120","source":"Crossref","is-referenced-by-count":6,"title":["Comparative Study of In Vitro Ocular Surface Cytotoxicity of a Fixed Combination of 0.5% Timolol\/1% Dorzolamide Eyedrop and Its Components with 0.005% Benzalkonium Chloride"],"prefix":"10.4265","volume":"17","author":[{"given":"MASAHIKO","family":"AYAKI","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ATSUO","family":"IWASAWA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YOSHIMI","family":"NIWANO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2789","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Ayaki, M., Iwasawa, A., and Inoue, Y. (2010) Toxicity to human corneal endothelial cells of major antiglaucoma medications with and without benzalkonium chloride. <I>Clinical Ophthalmology<\/I>, <B>4<\/B>, 1217-1222.","DOI":"10.2147\/OPTH.S13708"},{"key":"2","unstructured":"Ayaki, M., and Iwasawa, A. (2011b) Critical concentration of benzalkonium chloride in eye drop for toxicity in cultured ocular surface cell lines. <I>Inv. Ophthalmol. Vis. Sci<\/I>., <B>52<\/B>, E-Abstract 1955."},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2010.03.001"},{"key":"4","unstructured":"Boyle, J.E., Ghosh, K., Gieser, D.K., and Adamsons, I.A. (1998) A randomized trial comparing the dorzolamide\/timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group. <I>Ophthalmology<\/I>, <B>105<\/B>, 1945-1951."},{"key":"5","unstructured":"Fechtner, R.D., Airaksinen, P.J., Getson, A.J., Lines, C.R., and Adamsons, I.A. (2004) COSOPT versus XALATAN Study Groups. Efficacy and tolerability of the dorzolamide 2%\/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. <I>Acta Ophthalmol. Scand<\/I>., <B>82<\/B>, 42-48."},{"key":"6","unstructured":"Francis, B.A., Du, L.T., Berke, S., Ehrenhaus, M., and Minckler, D.S. (2004) Cosopt Study Group. Comparing the fixed combination dorzolamide-timolol (Cosopt) to concomitant administration of 2% dorzolamide (Trusopt) and 0.5% timolol. a randomized controlled trial and a replacement study. <I>J. Clin. Pharm. Ther<\/I>., <B>29<\/B>, 375-380."},{"key":"7","doi-asserted-by":"crossref","unstructured":"Hutzelmann, J., Owens, S., Shedden, A., Adamsons, I., and Vargas, E. (1998) Comparison of the safety and efficacy of the fixed combination of dorzolamide\/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group. <I>Br. J. Ophthalmol<\/I>., <B>82<\/B>, 1249-53.","DOI":"10.1136\/bjo.82.11.1249"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Ishibashi, T., Yokoi, N., and Kinoshita, S. (2003) Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. <I>J. Glaucoma<\/I>, <B>12<\/B>, 486-490.","DOI":"10.1097\/00061198-200312000-00008"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e31815cf651"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Konstas, A.G., Kozobolis, V.P., Tsironi, S., Makridaki, I., Efremova, R., and Stewart, W.C. (2008) Comparison of the 24 hour intraocular pressure-lowering effects of latanoprost and dorzolamide\/timolol fixed combination after 2 and 6 months of treatment. <I>Ophthalmology<\/I>, <B>115<\/B>, 99-103.","DOI":"10.1016\/j.ophtha.2007.03.007"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Lass, J.H., Khosrof, S.A., Laurence, J.K., Horwitz, B., Ghosh, K., and Adamsons, I. (1998) A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol. Dorzolamide Corneal Effects Study Group. <I>Arch. Ophthalmol<\/I>., <B>116<\/B>, 1003-1010.","DOI":"10.1001\/archopht.116.8.1003"},{"key":"12","unstructured":"Miglior, S., Grunden, J.W., and Kwok, K. (2010) Xalacom\/Cosopt European Study Group. Efficacy and safety of fixed combinations of latanoprost\/timolol and dorzolamide\/timolol in open-angle glaucoma or ocular hypertension. <I>Eye<\/I> (<I>Lond<\/I>) , <B>24<\/B>, 1234-1242."},{"key":"13","doi-asserted-by":"crossref","unstructured":"Nordstrom, B.L., Friedman, D.S., Mozaffari, E., Quigley, H.A., and Walker, A.M. (2005) Persistence and adherence with topical glaucoma therapy. <I>Am. J. Ophthalmol<\/I>., <B>140<\/B>, 598-606.","DOI":"10.1016\/j.ajo.2005.04.051"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Okeke, C.O., Quigley, H.A., Jampel, H.D., Ying, G.S., Plyler, R.J., and Jiang, Y. (2009) Interventions improve poor adherence with once daily glaucoma medications in electronically monitored patients. <I>Ophthalmology<\/I>, <B>116<\/B>, 2286-2293.","DOI":"10.1016\/j.ophtha.2009.05.026"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1159\/000055579"},{"key":"16","unstructured":"Strohmaier, K., Snyder, E., DuBiner, H., and Adamsons, I. (1998) The efficacy and safety of the dorzolamide\/timolol combination versus the concomitant administration of its components. Dorzolamide\/Timolol Study Group. <I>Ophthalmology<\/I>, <B>105<\/B>, 1936-1944."},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.59.11.667"}],"container-title":["Biocontrol Science"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T19:36:08Z","timestamp":1621539368000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bio\/17\/3\/17_115\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.4265\/bio.17.115","relation":{},"ISSN":["1342-4815","1884-0205"],"issn-type":[{"value":"1342-4815","type":"print"},{"value":"1884-0205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}